Fluciclovine F 18 Brand Name– Axumin
What is Fluciclovine F 18
Fluciclovine F 18 is an intravenous, radioactive diagnostic agent for use with positron emission tomography (PET) to evaluate men with suspected prostate cancer recurrence.
Following intravenous administration, fluciclovine F 18 is actively transported into prostate cancer cells, where peak accumulation occurs 4 to 10 minutes after the injection.
Localization of prostate cancer recurrence in sites typical for prostate cancer recurrence is based on fluciclovine F 18 uptake in comparison with normal tissue background.
However, because fluciclovine F 18 is not specific for prostate cancer, a positive or negative image does not confirm or rule out the presence of recurrent prostate cancer. An area identified by the PET scan as being a suspected recurrence site should be histopathologically evaluated for confirmation.
Fluciclovine F 18 was FDA-approved in May 2016.
Indications
- positron emission tomography (PET) imaging
For use during positron emission tomography (PET) imaging to evaluate men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) concentrations following prior treatment
NOTE: This drug is a radiopharmaceutical and should only be administered by individuals specifically trained in the handling of radioactive material.
NOTE: Dosage measured in megabecquerels (MBq) and millicuries (mCi).
Side Effects
- dysgeusia
- erythema
- injection site reaction
Adverse reactions were observed in 1% or less of fluciclovine F 18 recipients during clinical trials. The most frequently reported adverse reactions were dysgeusia and injection site reaction (i.e., pain or erythema)
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- accidental exposure
- breast-feeding
- females
- pregnancy
- radiation exposure
Interactions
No information is available regarding drug interactions associated with Fluciclovine F 18
